N4-hydroxycytidine and derivatives and anti-viral uses related thereto
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.
1. A compound represented by the formula:
2. A compound selected from the group consisting of pharmaceutically acceptable salts of
3. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:
5. A method of treating a human coronavirus, SARS coronavirus, MERS coronavirus, Venezuelan equine encephalitis virus, or influenza A virus in a patient in need thereof comprising administering to the patient in need thereof an effective amount of a compound represented by the formula:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the patient in need thereof is human.
7. A method of treating a human coronavirus infection in a patient in need thereof comprising administering to the patient an effective amount of a compound represented by the formula:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 7 , wherein the patient in need thereof is human.
9. A method of treating a human coronavirus infection in a patient in need thereof comprising administering to the patient an effective amount of a compound represented by the formula:
10. The method of claim 9 , wherein the patient in need thereof is human.